Applied DNA Sciences held its 2024 annual meeting on September 30, 2024, where shareholders approved all four proposals. The election of six directors to serve until the 2025 annual meeting was passed, with each nominee receiving over 2.3 million votes in favor.Shareholders ratified the appointment of Marcum LLP as the company's independent registered public accounting firm for the fiscal year ending September 30, 2024, with 4,411,771 votes in favor. Additionally, the board was granted discretionary authority to implement a reverse stock split at a ratio between 1:5 and 1:50 within the next 12 months.The final proposal, approving the exercisability of certain common stock purchase warrants issued on May 28, 2024, in accordance with Nasdaq Listing Rule 5635(d), was also passed. These voting results are final, marking a successful annual meeting for Applied DNA Sciences.

Applied DNA Sciences held its 2024 annual meeting on September 30, 2024, where shareholders approved all four proposals. The election of six directors to serve until the 2025 annual meeting was passed, with each nominee receiving over 2.3 million votes in favor.Shareholders ratified the appointment of Marcum LLP as the company's independent registered public accounting firm for the fiscal year ending September 30, 2024, with 4,411,771 votes in favor. Additionally, the board was granted discretionary authority to implement a reverse stock split at a ratio between 1:5 and 1:50 within the next 12 months.The final proposal, approving the exercisability of certain common stock purchase warrants issued on May 28, 2024, in accordance with Nasdaq Listing Rule 5635(d), was also passed. These voting results are final, marking a successful annual meeting for Applied DNA Sciences.